Refining eligibility criteria of unit selection for myeloablative cord blood transplantation in acute leukemia: Real-world experience of a referral center.

ABSTRACT: The algorithm for cord blood (CB) unit selection is still somewhat ambiguous. We retrospectively analyzed 620 cases of acute leukemia between 2015 and 2020, who were treated with myeloablative single-unit umbilical CB transplantation (UCBT). We found that, when human leukocyte antigen (HLA) mismatch was ≤3/10, CD34⁺ cell dosage <0.83 × 10⁵/kg-considerably lower than prevalent guidelines-was permissible without affecting survival. Moreover, synergy between donor killer-cell immunoglobulin-like receptors (KIR) haplotypes-B and donor-recipient HLA-C mismatch protected against relapse-related mortality. We submit that minimum required CD34⁺ cell dosage can possibly be relaxed to broaden access to UCBT, and donor KIR genotyping should be considered during unit s

SUBMITTER: Sun Z 

PROVIDER: S-EPMC10188464 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature